Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Andrew Tieniber"'
Autor:
Ferdinand Rossi, Mengyuan Liu, Andrew Tieniber, Mark S. Etherington, Andrew Hanna, Gerardo A. Vitiello, Nesteene J. Param, Kevin Do, Laura Wang, Cristina R. Antonescu, Shan Zeng, Jennifer Q. Zhang, Ronald P. DeMatteo
Publikováno v:
Clinical Cancer Research. 29:2144-2157
Purpose: To create an in vivo model of PDGFRA D842V-mutant gastrointestinal stromal tumor (GIST) and identify the mechanism of tumor persistence following avapritinib therapy. Experimental Design: We created a patient-derived xenograft (PDX) of PDGFR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fed41f74cb824ec4a2f1cda09e49008f
https://doi.org/10.1158/1078-0432.ccr-22-0533
https://doi.org/10.1158/1078-0432.ccr-22-0533
Autor:
Ronald P. DeMatteo, Jennifer Q. Zhang, Shan Zeng, Cristina R. Antonescu, Laura Wang, Kevin Do, Nesteene J. Param, Gerardo A. Vitiello, Andrew Hanna, Mark S. Etherington, Andrew Tieniber, Mengyuan Liu, Ferdinand Rossi
Supplemental Figure 1.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::932eab0071328eca61301666575efc60
https://doi.org/10.1158/1078-0432.22651654.v1
https://doi.org/10.1158/1078-0432.22651654.v1
Autor:
Ronald P. DeMatteo, Jennifer Q. Zhang, Shan Zeng, Cristina R. Antonescu, Laura Wang, Kevin Do, Nesteene J. Param, Gerardo A. Vitiello, Andrew Hanna, Mark S. Etherington, Andrew Tieniber, Mengyuan Liu, Ferdinand Rossi
Supplemental Figure 8.Relative MYLK mRNA expression by qPCR in GIST PDGFRA D842V PDXs treated with vehicle(Veh) or imatinib (IM) for 2 weeks.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::002022ffc6429b39d54180bdcfdbb0c7
https://doi.org/10.1158/1078-0432.22651630.v1
https://doi.org/10.1158/1078-0432.22651630.v1
Autor:
Ronald P. DeMatteo, Jennifer Q. Zhang, Shan Zeng, Cristina R. Antonescu, Laura Wang, Kevin Do, Nesteene J. Param, Gerardo A. Vitiello, Andrew Hanna, Mark S. Etherington, Andrew Tieniber, Mengyuan Liu, Ferdinand Rossi
Supplemental Figure 5.Short term culture of cells derived from PDGFRA D842V PDXs are tumor cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d370e6bf1381370fd2e9b47d6be1b2d
https://doi.org/10.1158/1078-0432.22651642
https://doi.org/10.1158/1078-0432.22651642
Autor:
Ronald P. DeMatteo, Jennifer Q. Zhang, Shan Zeng, Cristina R. Antonescu, Laura Wang, Kevin Do, Nesteene J. Param, Gerardo A. Vitiello, Andrew Hanna, Mark S. Etherington, Andrew Tieniber, Mengyuan Liu, Ferdinand Rossi
Supplemental Figure 3. GIST PDGFRA D842V PDXs are not sensitive to crenolanib.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::094b1bf9fdb23e92ce2a420e3025efa9
https://doi.org/10.1158/1078-0432.22651648.v1
https://doi.org/10.1158/1078-0432.22651648.v1
Autor:
Ronald P. DeMatteo, Jennifer Q. Zhang, Shan Zeng, Cristina R. Antonescu, Laura Wang, Kevin Do, Nesteene J. Param, Gerardo A. Vitiello, Andrew Hanna, Mark S. Etherington, Andrew Tieniber, Mengyuan Liu, Ferdinand Rossi
Supplemental Figure 7.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56c08442cbb17054a477469feca3c07d
https://doi.org/10.1158/1078-0432.22651633
https://doi.org/10.1158/1078-0432.22651633
Autor:
Ronald P. DeMatteo, Jennifer Q. Zhang, Shan Zeng, Cristina R. Antonescu, Laura Wang, Kevin Do, Nesteene J. Param, Gerardo A. Vitiello, Andrew Hanna, Mark S. Etherington, Andrew Tieniber, Mengyuan Liu, Ferdinand Rossi
Supplemental Figure 4.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac32aab5ac6d9413aa08a7989d9648cf
https://doi.org/10.1158/1078-0432.22651645.v1
https://doi.org/10.1158/1078-0432.22651645.v1
Autor:
Ronald P. DeMatteo, Jennifer Q. Zhang, Shan Zeng, Cristina R. Antonescu, Laura Wang, Kevin Do, Nesteene J. Param, Gerardo A. Vitiello, Andrew Hanna, Mark S. Etherington, Andrew Tieniber, Mengyuan Liu, Ferdinand Rossi
Purpose:To create an in vivo model of PDGFRA D842V-mutant gastrointestinal stromal tumor (GIST) and identify the mechanism of tumor persistence following avapritinib therapy.Experimental Design:We created a patient-derived xenograft (PDX) of PDGFRA D
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01aa5e516c830ea0ac7fc7bbac160e48
https://doi.org/10.1158/1078-0432.c.6604906
https://doi.org/10.1158/1078-0432.c.6604906
Autor:
Ronald P. DeMatteo, Jennifer Q. Zhang, Shan Zeng, Cristina R. Antonescu, Laura Wang, Kevin Do, Nesteene J. Param, Gerardo A. Vitiello, Andrew Hanna, Mark S. Etherington, Andrew Tieniber, Mengyuan Liu, Ferdinand Rossi
Supplemental Figure 6.Cell survival of GIST T1 cells treated with imatinib or avapritinib for 72h in complete media.Each data point represents an average of 10 wells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::196aa37791a5be757fbcf8160010722a
https://doi.org/10.1158/1078-0432.22651639.v1
https://doi.org/10.1158/1078-0432.22651639.v1
Autor:
Andrew Tieniber, Andrew Hanna, Benjamin Medina, Kevin Do, Lillian Levin, Ferdiando Rossi, Ronald DeMatteo
Publikováno v:
Cancer Immunology Research. 10:P050-P050
Introduction: Targeted therapy with tyrosine kinase inhibitors (TKI) including imatinib is effective in treating gastrointestinal stromal tumor (GIST), but resistance often develops within 18 months. Despite a robust immune T cell infiltrate, combini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ce7ea58ef4215be67ce544e271f58ce
https://doi.org/10.1158/2326-6074.tumimm21-p050
https://doi.org/10.1158/2326-6074.tumimm21-p050